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Introduction
PARK2 is a gene spanning an extremely large chromosomal region of 1.36 Mbs. This large gene spans the most unstable region within the highly unstable FRA6E common fragile site (CFS), and our novel hypothesis that received Department of Defense Ovarian Cancer Research Program funding was that Parkin (and possibly other large CFS genes, including FHIT and WWOX) is part of a stress response system that is disrupted during the development of ovarian cancer. We had three Specific Aims in our proposal. The first goal was to determine if inactivation of Parkin does contribute to the development of ovarian cancer. Our second aim was to inactivate the expression of Parkin, FHIT and WWOX, singly and in combination, in normal ovarian epithelial cells and determine if this had any phenotypic effects on those cells. Our final specific aim was to directly determine if Parkin functions as part of a stress-response network within cells. We proposed to accomplish this by treating VOSE cells with a variety of genotoxic and cellular stresses and then observe the effect on the expression of the Parkin protein. We finally proposed to examine and stress VOSE cells that had FHIT and/or WWOX inactivated to determine if this altered Parkin expression.
Body
We would like to thank the Department of Defense for their support of our work. The study and characterization of common fragile sites has been a difficult field because instability in these regions extends for multiple megabases and the genes in these regions, especially the large genes, have not turned out to be traditional mutational targets in cancer. As a result, there is a notion that CFS regions are merely highly unstable chromosomal positions and that genes in these regions are merely passengers to the instability surrounding them, rather than important players in cancer development. Our laboratory has been working on the cloning and characterization of these regions for many years and it is only with the recent availability of complete genome sequences for humans, mice and rats that important insights about the CFS regions and the genes contained within them have come to light. The CFS regions, in spite of being among the most unstable chromosomal regions, are highly evolutionarily conserved as are the large genes contained within them. The co-conservation of the large genes and the highly unstable regions suggests that the two function together somehow. Complete genomic resources have greatly facilitated the characterization of the CFS regions and we have now localized over 1/3 of the 90 described CFSs. Many of these regions contain genes similar in size to Parkin; thus observations that we make about Parkin, FHIT and WWOX may be applicable to many of large CFS genes. We believe that the entire group of large CFS genes function to respond to different types of stress. In addition, the large CFS genes are highly susceptible to alterations in developing cancer cells and as a group these genes may make significant contributions to the development of ovarian cancer. The current paradigm to explain the development of most epithelial tumors is that alterations in as few as 5-7 tumor suppressors and oncogenes transform normal epithelium into invasive cancer. We believe that these initial alterations trigger increased genomic instability and this then causes alterations in multiple genes, including many of the large CFS genes. These cumulatively cause dramatic changes in the phenotype of the resulting cells, and are also responsible for the tremendous heterogeneity observed in different cancers. We hope to develop sufficient preliminary results from Department of Defense support so that we can submit more competitive proposals to the National Cancer Institute to further characterize these important chromosomal regions.
In the past year we have made progress on each of the three Specific Aims. We will describe in detail the work that was completed for each Specific Aim.
Specific Aim 1: To analyze the effect of reintroducing PARK2 into ovarian cancer cell lines without endogenous Park2 expression. We took two ovarian cancer cell lines, OV202 and SKOV3, that had no endogenous Parkin expression and established stable Parkin-expressing cell lines. In addition, we found that Parkin expression was completely abrogated in all of the hepatocellular carcinoma cell lines that we examined, so we also introduced Parkin into two HCC cell lines. After establishing stable Parkin-expressing cancer cell lines, we performed colony formation assays and cell proliferation assays to detect whether Parkin expression would modulate cell growth. The colony formation assays revealed that there was no significant difference between Parkin-expressing clones and vector-only clones; please see the figure below. However, cell proliferation assays showed significant growth retardation in Parkin-expressing clones compared with vector-only clones. These data indicate that Parkin expression can modulate cancer cell growth. The Figures below show the cell proliferation assays comparing Parkin-expressing clones to vector-only clones.
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We then analyzed the effect of Parkin expression on cellular response to different stress treatments. We tested ovarian cancer cell lines for the effects of various stress treatments, including DNA damage, chemotherapeutic drugs, and mitochondria-dependent cell death. We observed that Parkin expression had no effect on DNA damage-induced apoptosis, including UV radiation, MMS and MMC-related DNA damage. However, Parkin expression protected cells from mitochondria-dependent apoptosis (ceramide induced apoptosis). The Figure below shows these results.
stress response assay 50- Figure 6 of this paper shows the sensitivity of two HCC cell lines, Hep3B and PLC5, to apoptotic inducers depending upon whether they have a stably transfected Parkin construct or the empty vector. We obtained results identical to this with the two ovarian cancer cell lines. In our original application we also proposed using expression profiling to determine which genes were affected by the re-expression of Parkin. However, we also proposed a similar expression profiling experiment which looked at inactivation of Parkin expression using RNAi strategies. We did the inactivation experiment this year and this will be summarized under the next specific aim.
40-
Specific Aim #2: To use RNAi strategies to inactivate the expression of the three large CFS genes (FHIT, WWOX and Parkin) in normal ovarian epithelial cells. There were several goals of this Specific Aim. The first goal was to determine if inactivation of multiple large CFS genes produced discernible phenotypic changes to cells. We therefore proposed strategies to inactivate the genes FHIT, Parkin and WWOX, singly and in combination. Our second goal was to use expression profiling to determine other genes affected by the inactivation of these large genes. In the past year we focused our efforts on the second goal. We established stable Parkin-expressing PLC5 (with homozygous Parkin deletion) and then used the U133A Affymetrix chips to compare mRNA levels of approximately 22,000 human genes in cell lines with and without Parkin expression. Parkin expression has been shown to be involved in cell and matrix interaction, so we sought to identify the difference of gene expression when cells were cultured on matrix (matrigel). As we expected, Parkin expression had high effects on gene expression when cultured on matrigel, indicating possible linkage between Parkin and cellular matrix interaction. Myogenic factor 5 potassium voltage-gated channel matrix metalloproteinase 10 heparin binding growth factor 8 TGF-beta receptor 1 regulator of G-protein signaling 9 protocadherin 8 (PCDH8) integrin beta 6 Gadd45A Specific Aim 3: To determine if'Parkin functions as part of a stress response network. The overall hypothesis that we would like to test is that the entire group of very large CFS genes function together as some type of stress-response network. We originally proposed to just examine the three known large CFS genes at the time (FHIT, Parkin and WWOX). We proposed to treat VOSE cells with various genotoxic and cellular stresses and then observe the effect of these on Parkin expression. We also proposed to observe VOSE cells with WWOX or FHIT inactivation to see if this had any effect on Parkin expression.
In the past year there has been a number of other very large CFS genes discovered. The first one was the 1.46 Mb GRID2 gene at 4q22.3. Michelle Debatisse's group demonstrated that this gene maps to a CFS in both mice and humans. In addition, spontaneous deletions of this gene in mice lead to the mouse mutant Lurcher, which lose 100% of their Purkinje cells postnatally. Interestingly, a spontaneous deletion which removed the Parkin gene and its neighbor PACRG results in another mouse neurological mutant called Quaker (viable).
Since there are a number of extremely large CFS genes, we contacted the University of California, Santa Cruz Human Genome Database to obtain lists of the largest known human, mouse and rat genes. We found that there were far more extremely large genes than anticipated. There are a total of 40 human genes that span greater than 1.0 Mb of genome sequence and another 200 that span between 500 Kb and 1.0 Mb. Interestingly, many of the largest human genes map to chromosomal bands known to contact a CFS. In the past year we have examined several other very large genes, including the 2.3 Mb CNTNAP2 gene, the 2.0 Mb DMD gene, and the 1.5 Mb DAB1 gene. We have discovered that each of these are large CFS genes. Thus far we have found that 6 of the 10 largest human genes are CFS genes. This is extremely important, as anything that we find out with Parkin, FHIT or WWOX may be generalized to all the large CFS genes.
We hypothesized that Parkin might be interacting with other large CFS genes. To test our hypothesis, we tested for possible functional interactions between WWOX and Parkin. The yeast two hybrid experiments revealed that Parkin interacts with wild type WOX 1 but not the mutant WOXI (Y33R). Co-immunoprecipitation confirmed the interaction between WOXI and Parkin as shown in Figure A . We also observed that Parkin expression specifically decreased wild type WOX1 protein level as shown in Figure B , but did not decrease the expression of mutant WOX1. Moreover, Parkin expression blocked WOX 1-induced apoptosis, which was consistent with our previous Specific Aim I observation that WOX1-induced apoptosis is mitochondria-dependent and is involved in the p53 and JNK pathway. In addition, Parkin expression protected mitochondrial swelling and blocked WOXl -induced cell death. We also found that Parkin expression markedly reduced the cytosolic protein level of WOXI ( Figure C ), and this reduction was abrogated by proteasome inhibitors. This suggests that Parkin, a ubiqutin E3 ligase, may degrade cytosolic WOXI. This is currently under investigation. To identify the possible interaction of Parkin and WOX1, Parkin-myc and WOX1-GFP plasmids were transfected into COS1 cells, and then total cellular protein was collected and subjected to co-immunoprecipitation. By use of anti-GFP and anti-myc antibody, respectively, we found that Parkin specifically precipitated with human WOXI and mouse WOX 1, not the GFP tag, indicating that Parkin interacts with WOX I in vivo.
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. Parkin expression decreased WOXI protein level. COSI cells were transiently transfected with different expression plasmids as indicated in the figure. Cytosol protein was collected and subjected to immunoblotting to detect the expression of GFP-WOXI varieties in the presence or absence of Parkin. Actin was used as an internal control. Parkin expression reduced the protein level of hWOXI and mWOX1, but not dominant negative (DN) WOXI and Y33R mutant WOX1.
Parkin expression decreased the cytosolic level of WOXI ( Figure C ). WOXI is a proapoptotic protein capable of interacting with p53. A large portion of endogenous WOX1 protein is located in the mitochondria, and the mitochondrion-targeting sequence has been mapped within the ADH domain. This is consistent with Parkin's location, as we found a proportion of Parkin was present in mitochondria. During apoptosis or stress responses, there is an increased synthesis of cytosolic WOX1, followed by translocation to the mitochondria. Most conclusively, by electron microscopy we have demonstrated an increased presence of WOX1 in the damaged mitochondria and condensed nuclei of retinal degenerating photoreceptors in rats. Induction of mitochondrial permeability transition by TNF, staurosporine, and atractyloside results in WOX1 release from the mitochondria and subsequent nuclear translocation.
Thus, we assume that the decrease in the cytosolic level of WOX1 by Parkin would block most of the pre-apoptotic function of WOXI, and meanwhile interfere with the translocation of WOX1. We transfected WOX1 and Parkin together into HEK293 cells and detected the cytosolic WOX1 level in the presence or absence of Parkin expression under the treatment of Staurosporine. As shown in Figure C below, without Parkin expression, the cytosolic WOXI level was abundant. With the staurosporine treatment, cytosolic WOXI was decreased due to translocation. However, with Parkin expression, we observed decreased cytosolic levels of WOX1 and blockage of translocation of WOX1 under staurosporine treatment. These data represent part of the mechanism by which Parkin blocks WOX I-induced apoptosis. 48hr after transfection, cells were incubated with staurosporine (5 uM) for indicated times, and cytosol was collected by use of NucBuster extraction kit (Novagen). mWOX I expression was detected by use of anti-GFP Abs, Actin was detected as an internal control.
Key Research Accomplishments
We had three Specific Aims to determine the role that Parkin plays in the development of ovarian cancer. These aims were:
Specific Aim 1: To analyze the effect of reintroducing PARK2 into ovarian cancer cell lines without endogenous Park2 expression.
Specific Aim #2: To use RNAi strategies to inactivate the expression of the three large CFS genes (FHIT, WWOX and Parkin) in normal ovarian evithelial cells.
Specific Aim 3:
To determine if Parkin functions as part of a stress response network.
Our key research accomplishments are:
(1) We have demonstrated that the reintroduction of Parkin into ovarian cancer cell lines (as well as cell lines from other cancers) results in cells that are more sensitive to inducers of apoptosis. This is consistent with our hypothesis that the inactivation of Parkin during the development of ovarian cancer contributes to the cancer phenotype.
(2) We have begun to demonstrate how Parkin interacts with another very large common fragile site gene, WWOX. Since WWOX has been shown to be functioning as a stress-response gene (this gene is specifically phosphorylated in response to stress and then binds to p53 to induce apoptosis), this provides further evidence that Parkin is also involved in cellular responses to stress.
(3) We now have evidence that many of the largest human genes (not just FHIT, Parkin and WWOX) are localized within common fragile site regions. The findings that we make with FHIT, Parkin and WWOX may be representative of what is occurring in all of the large CFS genes.
Conclusions
We are continuing to study the very exciting Parkin gene to determine its function in the normal cell and understand how loss of Parkin expression contributes to the development of ovarian cancer. We now know that loss of expression of this gene is associated with greater resistance to induction of apoptosis and that this gene interacts with another large CFS gene, WWOX. In the next year we will be examining how this gene functions to respond to stress. In addition, we will look for more functional connections between Parkin and other large CFS genes involved in stress response.
INTRODUCTION
and/or breaks when cells are cultured in the pres-
The Parkin gene was first identified as a muta-ence of specific inhibitors of DNA replication, such tional (point mutation and exonic deletion) target as aphidicolin (Rao et al., 1988) . The two most in a proportion of patients with autosomal recessive active CFSs are FRA3B, at 3p1l4.2 (Becker et al., juvenile parkinsonism (ARJP) (Hattori, 1998; , and FRA16D, at 16q23.2 (Nlangelsdorf et Kitada et al., 1998; Periquet et al., 2001) . . These CIFSs (FRA3B, FRA16D, and
Parkin gene contains 12 small exons and encodes FRA6E) also occur in chromosomal regions that are an E3 ligase, which is comprised of 465 amino acids frequently deleted in HCC and many other tumor with a molecular mass of approximately 52,000 Da.
types (Yuan et al., 2000; Yakicier et al., 2001 ; Deni-The gene itself is extremely large and spans 1.5 son et al., 2003a son et al., : HLuebner et al., 2003 . Instability Nib of genomic DNA in chromosomal band 6q 2 6 . within FRA3B and FRA16D extends for 4.0 and Various deletions and point mutations in Parkin 2.0 Nib, respectively, and spanning the most unstahave been discovered in patients with ARJIP ble regions within these CFSs are two extremely (Hedrich et al., 2002; Rawal et al., 2003, Tan, large genes, FHIT(fragile histidine triad), which is 2003). However, large genome rearrangements re-1.4 Nib (Ohta et al., 1996) , and RI1VOX (WW dosuiting in the deletion or duplication of Parkin exons account for approximately 50% of the alterations observed in patients with ARJP. fragile site (Kahkonen, 1988 main-containing oxidoreductase), which is 1.0 M)Ib for Parkin gene alteration. We also observed de- (Bednarek et al., 2000) . Alterations in these two creased or absent Parkin protein expression in genes are frequently observed in multiple tumor HCC cell lines and primary tumors. Stable exprcstypes, and the proteins encoded by these genes are sion of the Parkin gene in PLC5 and Hcp3B 11C(C absent or decreased in many different cancers (Lee cells resulted in enhanced sensitivity to apoptosis et al., 2001; Driouch et al., 2002; Yendamuri et al., induced by cell-cycle inhibitors. 2003). However, FHIT and WWOXdo not appear to be traditional mutational targets in cancer because MATERIAL AND METHODS point mutations are rarely found within them, although many tumors have larger heterozygous de-Reagents letions within the CFS regions that presumably Parkin antibodies were obtained from CcilSigresult in inactivation of gene expression.
naling (Beverly, MA) and Chemicon (Temecula, We recently characterized the FRA6E region CA). Parkin expression constructs were kindly proand found that instability within this region exvided by I)r. Paul J. Lockhart (Mayo Clinic, Jacktended for 3.5 Mb (Denison et al., 2003a) . A num-sonville, FL). Plasmid pcl)NA3.1 (+)/myc-his A ber of small genes are encoded within the centro-was obtained from Invitrogen (Carlsbad, CA) and meric half of FRA6E, but the distal half, which also was used as a transfection vector-only control. contains its most unstable region, is spanned by the Normal liver tissues and HCC primary tumors were 1.5-Mb Parkin gene. We found that Parkin expresobtained from surgical sections performed at the sion was decreased in 60% of primary ovarian tu-Mayo Clinic (Rochester, MN). Staurosporine, Trimors, and we also detected tumor-specific alternachostatin A (TSA), sodium butyrate, and DAPI tive transcripts of Parkin in primary ovarian tumors were purchased from Sigma-Aldrich ( cultured according to ATCC's protocols. Western They also detected absent or diminished Parkin blotting was performed according to standard expression in breast and ovarian cancer cell lines methods. Signals were detected using the EC1I and in primary tumors. system (Amersham Pharmacia Biotech, Piscataway, These three CFS regions and the large genes NJ). contained within them, therefore, have a number of similarities. A more detailed analysis of FHII'
Screening for Homozygous Exonic Deletions in revealed that this gene is inactivated in many tu-Cancer-Derived Cell Lines mor types and that the inactivation of this gene can Primers unique for each of Parkin's 12 exons be detected early in cancer development, even in were synthesized according to Kitada (Kitada et al., premalignant lesions (Birrer et al., 1999; Hao et al., 1998) at the Nlayo Clinic Molecular Core Facility 2000). The reintroduction of FHIT into some, but (Rochester, MN) and tested on a l)NA panel connot all, cancer-derived cell lines can inhibit cell sisting of genomic DNA isolated from 50 cancergrowth and, in some instances, can induce apoptoderived cell lines. Briefly, genomic I)NA was isosis (Ji et al., 1999; Sard et al., 1999) . Similar alterlated from cells by standard phenol-chloroforrm ations have been detected in IflUOX in multiple methods. The PCR mix (20 p. 1 reaction volume) tumor types, and cellular stress causes IfVOX to contained 20 ng of genomic DNA, I X PCR buffer, interact with P53 to induce apoptosis (Chang et al., 2 W1 of dNTP (10 mNl), 0.5 p.M primers, and 1 I. 2002, 2003) . Hence, these large CFS genes are Taq polymerase (Promega, Nladison, WI). Thc frequently inactivated in tumors, and their loss can conditions for amplification were: 94'(C for 3 mmin: play an important role in tumor development, then 35 cycles of 95°C for 30 sec, 50(C for 30 sec. We report here on a study in which we examined and 72'C for 30 sec; with a final extension of 72'C 11 hepatocellular carcinoma cell lines in a search for 10 min. according to the manufacturer's instructions. To (2001) . Eleven HCC cell lines and two normal liver amplify the complete coding region of the Parkin tissue samples (positive controls) were used as gene, 5 Rg of total RNA \as subjected to RT-PCR shown in Table 1 . The genomic DNA was isolated using 3 sets of primers, according to Kuroda (2001) . using standard phenol-chloroform methods. The Exons 1-6: forward, . -GACCATGA !AGT-PCR samples (20.0 pI. total volume) contained 50 GTT-3' (nt 98-114): and reverse, 5'-GATGTng of genomic L)NA, 1X PCR buffer (supplied TCCG ACT''ATTTGTFGCGATCAGG'I'-3' (nt with enzyme), 4 mNI NIgCl,. 0.2 mIN dNTP, 0.3x 781-809); exons 2-9: forward,. 5'-CTGA GGAAT-Sybr green (Molecular Probes, Inc., Eugene, OR), GACTG GACTG-3' (nt 249-267); reverse, 5'-0.05% BSA, 0.5 p.M concentration of forward and CACTCCTCTGCACCAT ACT-3' (nt 1051-1069); reverse primers for the specific exons, and 0.1 U and exons 9-12: forward, 5'-GTACAA(CCYGTACC Platinum Taq polymerase (Invitrogen, Carlsbad, AGCA GTATG-3' (nt 1034-1056); reverse, 5'-CTA-CA). The conditions for amplification were as pre-CACGTCG AACCAGT GGTC -3' (nt 1479-1499). viouslv described. The gene dosage ratio of Parkin
The PCR reactions were performed as above, and the exons was compared to the control gene P-actin amplified products were cloned into the pCR4-(H!B) in order to identify deletions and/or dupli-TOPO vector (Invitrogen, Carlsbad, CA) and secations of each exon of Parkin. A standard curve quenced by the Molecular Biology Core Facility at was generated by use of human genomic DNA the Nlayo Clinic, Rochester.
(Roche Diagnostics, Indianapolis, IN) in concen-
Construction of Stably Parkin-Expressing PICS trations of 5, 1.25, and 0.3125 ng/Vll. All standards and Hep3B Cell Lines (and samples) were amplified in duplicate, followed by calculation of a regression curve, based on PLC5 and Hep3B cells were maintained in which sample concentrations were inferred and ac-MEM medium (Invitrogen, Carlsbad, CA) supplecepted only when within the range of the standard mented with 10% fetal bovine serum. The Parkin tem plates. expression vector was pcDNA3.1/Parkin, and the vector-only control was pcI)NA3.1. Before transfection, the exponentially groving cells were Fluorescence In Situ Hybridization washed with serum-free medium and transfected Mctaphasc/interphasc preparations were obwith 5 p.g of plasmids and 20 pli of IUpofcctamin tained from each of the HCC cell lines. Cell har-2000 (Invitrogen) according to the manufacturer's vest and metaphase preparations were performed instructions. After a 5-h incubation, complete by routine cytogenetic techniques. Three different growth medium was added. After 48 h, transfected bacterial artificial chromosomes (BACs) were used cells were selected in 400 [tg/ml Geneticin for 2-3 to determine (1) whether any HICC cell line exhibweeks. Subsequently, cloning cylinders were used ited aneuploidy for chromosome 6 and (2) the Parto clone individual colonies. For each cell line, kin dosage level for each cell line. The three BACs eight clones were selected and detected by \Vestwere a centromere probe specific to chromosome 6, ern blotting against the Parkin antibody. For each RP-1 179P19 (which contains a portion of exons 3
Parkin-expressing cell line, we chose the three and 4 of Parkin), and C'ID-264317 (which contains most abundant expressing clones for further study. a portion of HBB). For clones RP-1 179P19 and C(TD-264317, 1 pRg of purified DNA was labeled Immunocytochemistry Detecting Parkin with biotin-16-dUTP (Boehringer/Roche, India-Localization napolis, IN) by nick translation, precipitated, and tarkin-expressing PLC5 and Hep3B cells as well hybridized to the interphase chromosomes accordas empty vector transfectants were plated in 4-well ing to the protocol described by Verma and Babu chambers in complete growth medium. After 24 hr, (1995) . Photomicroscopy was performed with a cells were washed three times with PBS and fixed Zeiss Axioplan 2 fluorescence microscope and in methanol (-20'C) for 10 min, followed by per- " =m A l meabilization with 0.1% Triton X-100 for 5 min. confirmed the deletion of exon 3, as the 3' end of Fixed cells were incubated in 5% normal goat seexon 2 was directly connected to the 5' end of exon rum for 1 hr and then incubated with anti-Parkin 4 ( Fig. 1 B) . primary antibody at 4°C overnight. Primary antibody was detected after incubation in FITC-con- the corresponding vector-only transfected cells tions of Parkin exons. The gene dosage ratio of the were plated at 5,000 cells/well in triplicate in 24-Parkin gene was compared to the control gene well plates with complete medium. For each cell P3-actin (HBB) in order to identify deletions and/or line, three independent clones were subjected to a duplications of whole exons of Parkin. The normal proliferation assay. The total cell number was mea-gene dosage for any Parkin exon as compared to sured every 2 days for a total of 10 days with the HBB was determined to a range of 0.8-1.2. D)osage MITS assay (Chemicon, Temecula, CA) according values less than 0.4, from 0.4 to 0.6, and from 1.4 to to the manufacturer's instructions.
1.6 were identified as representing an HID, hi). and heterozygous duplications, respectively, for that Analysis of Apoptosis Parkin exon. However, these ratios specifically re-Hep3B and PLC5 cells (Parkin-expressing or flected the gene dosage levels for karvotypically vector-transfected only) were plated in 6-well normal individual cells. plates at a density of 200,000 cells/well. Before Karyotypic analysis of primary tumors, as well as treatment, cells were washed with PBS and of tumor-derived cell lines, has demonstrated that changed to the serum-free medium. Staurosporine, most cancers are aneuploid, with variation in both 'T'SA, and sodium butyrate were added to the se-chromosome number and structure (Knudson, rum-free medium at the indicated concentrations 2001). Hence, we utilized a fluorescence in situ and incubated for 5 hr (staurosporine) or 24 hr hybridization (FISH)-based technique to quanti-(TSA and sodium butyrate). Apoptosis was mea-tate the copy number of 6q sequences surrounding sured by assessing the number of cells containing Pat-kin in the HCC cell lines (Fig. 2) . We then nuclear changes (chromatin condensation and no-modified the gene dosage ratios in order to accuclear fragmentation) after staining with DAPI (final rately reflect the changes in the gene dosage ratio concentration of 5 pRg/ml). After incubation in the of Parkin exon to 1tBB that could calculate the dark with DAPI for 20 min, cells were examined by exon variation observed among the cell lines. We fluorescence microscopy (Nikon Eclipse TF200; analyzed a total of 50 interphase cells for each of Nikon Corp., Tokyo, Japan). '[he experiments the 11 cell lines in order to determine the ratio of were performed in triplicate, and at least 300 cells observed hybridization signals of Partkin to HIB were counted in each individual treatment.
( Table 1) . Each HCC cell line had a unique, relatively "normal" Parkin gene dosage ratio. For ex-
RESULTS
ample, for SNU182 cells, the normal ratio is bee tween 1.3 and 1.9, whereas for Hep3B cells the Screening of 50 Cancer-Derived Cell Lines for normal ratio is 1.4-2.1.
Homozygous Deletion of Parkin Exons
Quantitative duplex PCR analysis of l,(C5 con-We screened each Parkin exon for homozygous firmed the HI) mapping data and identified PlIC5 deletion in a panel of 50 cancer-derived cell lines as having a lhomozVgous deletion of exon 3 (Parkin/ by using genome DNA amplification (data not HBB ratio of 0.03; Table 1) , as well as a heterozyshown). Only a single cell line, PLC5, had a de-gous deletion of exon 4 (Parkin/HBB ratio of 0.33; tectable homozygous deletion of a Parkin exon. Table 1 ). SNU398 had a heterozygous deletion of This cell line exhibited no amplification of exon 3 exons 4 and 8, SK-Hepl had a heterozVgous dele- (Fig. 1A) . Sequence analysis of the PCR-amplified tion ofexon 3, and Hep3B had both a heterozygous cDNA of Parkin in the PILC5 cells using three sets duplication of exon 5 and a heterozygous deletion of primers specific to exons 1-6, 2-9, and 9-12 of exon 9 ( Table 1) Parkin Protein Expression in HCC Cell Lines and using two different Parkin antibodies, which were Primary Tumors raised against amino acids 295-311 of human Par-Using Western blotting, we found that Parkin kin and full-length Parkin, respectively. We also protein was completely absent or diminished in all performed immunoblotting on extracts from ilC(C 11 HCC cell lines tested compared with its level in primary tumors. We found that more than 50% of normal liver tissue. As shown in Figure 3A , only primary tumors had diminished or absent Parkin SNU423, HepG2, SN1387, and SNIT475 had Par-protein expression compared to the benign pair kin protein expression. These data were confirmed (Fig. 3B) . To determine whether Parkin expression affects potential physiological differences before and after cell growth, we performed proliferation assays on Parlkin gene expression. We picked up 8 individual vector-only PILC5 and Hep3B cells and on three clones after transfection and detected Parkin proindependent Parkin-expressing clones of each cell tein expression by using Western blotting (Fig.  line , PLOC, and Hep3B. In each well of 24-well 4A). We chose the three most abundant Parkinplates, 5,000 cells were plated, and the NITS assay expressing clones for use in the proliferation and was used to measure the cell number every 2 days apoptosis assays. Meanwhile, using immunocytoover a 10-day period (Fig. 5 ). Parkin-expressing chemistry, we showed that in both the PLC5 and clones grew more slowly than empty vector trans-Hep3B transfected cells, Parkin protein was mostly fectants in both the PLC5 and Hep3B cell lines.
localized in the cytoplasm and that there was no To examine the effects of Parkin expression on colocalization with DAPI (nuclear) (Fig. 4B ). Reapoptosis, Parkin-expressing clones and vector- transfected clones were exposed to different treat-Pa-kin-transfected clones. These results showed ments. Three apoptosis-inducing drugs were used that Parkin enhanced the sensitivity of TSA-and in the apoptosis induction assay: staurosporine, butvrate-induced apoptosis ( Fig. 6A-C) . TSA, and sodium butyrate. Staurosporine is a widely used proapoptotic stimulus that acts as a broad-spectrum kinase inhibitor. Both TSA and Common fragile sites are highly unstable chrosodium butyrate are potent and specific inhibitors mosomal regions that predispose chromosomes to of mammalian histone deacetylase, which induce breakage and rearrangement (Michels, 1985 ; Smith cell apoptosis by regulating the eukar-otic cell cy-et al., 1998) . They are present in all individuals, but tie. For staurosporine treatment, cells were incu-some are more highly expressed than others. More hated at concentration ranging from 0 to 5 l.M for highly expressed CFSs include FRA3B (3p1 4 .2), 5 h and then stained with DAP1 to detect, by FRA16D (16q2 3 .2), and FRA6E (6q26). Interestfluorescence microscopy, nuclear condensation and ingly, all three regions were found to be consisfragments, which are evidence of apoptotic cells tently deleted in HCC (Kitay-Cohen et al., 2001; (Fig. 6) . In the other two treatments, the concen- Yakicier et al., 2001; Zhao et al., 2003) as well as in trations of TSA ranged from 0 to 1 p•l and of ovarian, breast, and prostate cancers. FRA3B, the sodium butyrate from 0 to 10 mNI. Parkin expres-most active CFS, spans 4.5 Mb within chromosome sion had no effect on staurosporine-induced apo-segment 3pI4.2, and the 1.4-Mb FHIT gene is in ptosis. In contrast, Parkin-expressing clones were the center of FRA3B (Ohta et al., 1996) . FHIT is a more sensitive to either TSA-or sodium butyrate-diadenosine triphosphate hydrolase whose subinduced apoptosis than were vector-transfected strates are produced in cells in response to stress clones. The effect was significant at low drug con- (Brenner et al., 2002) . The reintroduction of FHIT centrations (TSA at 0.25 and 0.5 l.LM, sodium bu-into specific cancer-derived cell lines results in the tyrate at I and 2 mM). Similar results were ob-induction of apoptosis (Ji et al., 1999; Sard et al., tained --
Hep3B/Parkin3
Par-kin was originally identified as a mutational 0,75target in patients with autosomal recessive juvenile parkinsonism, a rare form of parkinsonisn associ-0ated with an early age of onset (Hattori, 1998; "Kitada et al., 1998; Periquet et al., 2001) . Mutations 0 in Plarkin have been demonstrated to be responsible for the pathogenesis of ARJI). Patients with ARJP have large deletions or duplications of Parkin 0.00 exons more frequently than point mutations, al-0 2 4 6 8 10 though 1-or 2-bp, even 40-bp, small-fragment de-Days letions have also been observed in patients (Hattori, 1998; Kitada et al., 1998; Periquet et al., 2001 : The Parkin-expressing clones grew more slowly than did the vector-only have been documented throughout the entire PIartransfectants.
kin gene, but the majority localize between exons 2 and 8 of Parkin, which correspond to the most unstable region within FRA6E. 1.0-Mb WW1VOX gene, which also has been found to
We tested a panel of 50 cancer-derived cell lines be frequently altered in multiple tumor types searching for homozygous deletions of Parkin cx- (Bednarek et al., 2000; Yakicier et al., 2001) . Chang ons. One [ICC cell line, PLC5, had a detectable et al. (2002, 2003) showed that cellular stress inhomozygous deletion encompassing exon 3 of Parduces phosphorylation of IWIWOX and that this kin. We then used the qtuantitative duplex P(;R phosphorylated protein functions to induce apoptotechniques of Hedrich et al. (2001) to characterize sis by binding to P53 protein. Hence, both CFS homozvgous and heterozygous deletions and dupligenes appear to play an important role within the cations of Par-kin exons in 11 HCCX cell lines. This cells, and loss of expression of one or both is cointechnique was developed to characterize Parkin monly observed in multiple tumor types, including alteration in ARJP patients, who are generally dip-HICC.
loid for 6q26 sequences. Because many cancer-Parkin is the third very large gene that has been derived cell lines are aneuploid, we utilized FIS11 mapped within a frequently deleted CFS region analysis to determine copy numbers of the 6(126 (Denison et al., 2(X)3a, 2003b). There are many simsequences in the 11 HCC cell lines. We then could ilarities between Parkin/FRA6E, FHI'JTFRA3B, and use quantitative duplex PCR to standardize the IIIVOX/FRA16D. FRA3B, FRA16D, and FRA6E are values obtained in order to determine accurately the three most active CFSs. Instability within each whether there were any deletions or duplications of A. Sodium Butyrate (mM) sodium butyrate (mM) Figure 6 . Parkin expression enhanced the sensitivity of Hep3B and PLC5/Parkin cells, and vector-only transfectants were subjected to PLC5 cells to apoptosis induced by TSA and sodium butyrate treatstaurosporine treatment (0, 0.5, I, 2, and 5 liM) for 5 h. Parkin I, 2, and ments. Parkin-expressing cells and vector-only cells were incubated at 3 refer to three different Parkin-expressing clones. (B) Effect of Parkin the indicated concentrations of TSA. After 24 h of incubation, cells expression on TSA-induced apoptosis. Cells were treated with TSA (0, were stained with DAPI (5 gig/ml) for 20 min. Apoptosis percentage was 0.25, 0.5, I tiM) for 24 h. (C) Effect of Parkin expression on sodium measured by counting the number of cells containing nuclear changes butyrate-induced apoptosis. Cells were incubated with sodium butyrate (condensation and fragments). The non-apoptotic cells remain intact. At (0, 1, 2.5, 5, 10 mM) for 24 h. The apoptosis percentage in three least three hundred cells were counted, and each experiment was treatments was measured by fluorescence microscopy nuclear counting performed in triplicate. (A) Effect of Parkin-expression on staurospoafter DAPI staining. rine-induced apoptosis. Three independent clones of Hep3B/Parkin,
75-
